Rob Michiels was elected as a member of the Company's Board of Directors in 2016. He is a 30plus-year veteran of the US medical device industry, both in corporate positions and as a serial startup entrepreneur. He most recently served as Chief Executive Officer of CardiAQ™ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation and which was acquired by Edwards Lifesciences late 2015. He previously served as President and Chief Operating Officer (COO) of CoreValve; and as President and COO of InterVentional Technologies. He helped drive both companies from cardiovascular start-ups to established market leaders, developing and marketing new and innovative interventional technologies which have strong synergies to the FEops story. Rob Michiels is also a founding partner of CONSILIUM Associates, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Masters in business administration (MBA) from Indiana University
Alexandra Tolia is Senior Investment Manager at PMV, where she directs investments in innovative Life Sciences ventures. Since 2011 she has served as board member in several biotech companies, including eTheRNA, Multiplicom, FEops, iTeos Therapeutics and Apitope. Prior to PMV she led the investment strategy at Hunza Ventures, where she was instrumental in establishing the fund's biotech portfolio in Europe and the US. For over a decade before joining the investment industry, Alexandra built an international scientific career, pioneering drug development initiatives in neurodegeneration and cardiovascular diseases, and managing key alliances between academia and the pharmaceutical industry. Alexandra holds a PhD in Medical Sciences from the University of Leuven, a degree in Management from the Solvay Brussels School of Economics and Management and is the author of several high-impact scientific publications.
Marc Lambrechts is Senior Investment Manager at Capricorn Venture Partners NV. Marc’s investment interests are related to technology fusion and more specifically ICT, digital healthcare, IoT and nanotechnology. Marc was in charge of the successful investments in a.o. Enfocus, FillFactory and Punch Powertrain. He serves on the board of FEops, Bluebee and Leuven.Inc Prior to joining Capricorn Venture Partners in March 1998 Marc served for six years as Senior Scientific Adviser at IWT and worked two years at the European R&D lab of Terumo Europe NV. Marc has a PhD in Electrical Engineering of the University of Leuven, more specifically on implantable biosensors.
Matthieu is a visionary entrepreneur with great people management and communication skills. Under his leadership FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in Engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling. In 2009 he followed the general management program ‘Technology Transfer’ at Vlerick Leuven Gent Management School. Matthieu is author of several high-impact scientific publications.
Guillaume is Investment Manager at Valiance, a London based investment firm. Guillaume is responsible for its portfolio of Life Sciences companies, investing growth capital into innovative medical technologies in Europe and in the US. Prior to that, Guillaume has a career in Investment Banking, advising large capitalization corporates on Mergers and Acquisitions and other corporate finance decisions including Capital Markets financing. Guillaume has experience in various sectors including Healthcare but also Consumer, Retail, Telecoms, e-Commerce, Oil & Gas. He graduated from ESSEC Business School in Paris.
Worked twenty-one years with Boston Scientific Corporation, in the most recent role as Vice President and General Manager, Transcatheter Aortic Valves (TAVR) from 2012 - 2017, was responsible for leading Boston Scientific into the global market for minimally invasive Transcather Aortic Valves and was intimately involved with the New Business Development Strategy for structural heart. He holds a B.S. Business Degree from the University of Minnesota, Minneapolis with concentration in Marketing and Logistics